866-997-4948(US-Canada Toll Free)

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 50 Pages



GlobalData, the industry analysis specialist, has released its new report, Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimated the ADHD market to be worth $3.82 billion in 2009 and it is forecast to remain stable with a very low growth of a CAGR of 0.2% annually for the next seven years, to reach $3.88 billion by 2017. This modest growth can be primarily attributed to population growth and increased prescription rates. However, a low treatment seeking rate, low diagnosis rate, combined with the availability of alternate options such as generics, behavioral and psychological therapies, diet changes, as well as the unknown cause of the disease, continue to pose significant challenges for prospective market entrants.

Scope

The report provides information on the key drivers and challenges of the ADHD market. Its scope includes: 

  • Annualized global ADHD market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as serotonin reuptake inhibitors, neuronal nicotine receptors agonists, dopamine reuptake inhibitors, AMPA type glutamate receptors.
  • Analysis of the current and future competition in the global ADHD market. Key market players covered are Sceile Pharma, AstraZeneca, Supernus Pharma, Cortex pharma.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global ADHD market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global ADHD market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Attention Deficit Hyperactivity Disorder: Introduction
2.1 Overview
2.2 GlobalData Pipeline Report Guidance

3 Attention Deficit Hyperactivity Disorder Therapeutics: Market Characterization
3.1 Attention Deficit Hyperactivity Disorder Market Size
3.2 Attention Deficit Hyperactivity Disorder Market Forecast and CAGR
3.3 Drivers and Barriers for Attention Deficit Hyperactivity Disorder Market
3.3.1 Drivers for Attention Deficit Hyperactivity Disorder Market
3.3.2 Barriers for Attention Deficit Hyperactivity Disorder Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 Attention-Deficit Hyperactivity Disorder Market: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the ADHD Market
4.3.1 Daytrana (methylphenidate transdermal system)
4.3.2 Vyvanse (lisdexamfetamine dimesylate, NRP-104, S-489)
4.3.3 Strattera (atomoxetine Hcl)
4.3.4 Intuniv (guanfacine hydrochloride, SPD 503, GXR)
4.3.5 Concerta (methylphenidate Hcl)
4.4 Key Takeaway

5 Attention Deficit Hyperactivity Disorder Market: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytical Framework
5.3 Attention-Deficit Hyperactivity Disorder Therapeutics - Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 ABT-894 (Sofinicline)
5.4.2 Eltoprazine
5.4.3 AZD3480 (TC-1734) (Isopronicline)
5.5 Attention Deficit Hyperactivity Disorder Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.6 Attention Deficit Hyperactivity Disorder Pipeline - Pipeline by Clinical Phases of Development
5.6.1 Attention Deficit Hyperactivity Disorder Therapeutics - Phase III Clinical Pipeline
5.6.2 Attention Deficit Hyperactivity Disorder Therapeutics - Phase II Clinical Pipeline
5.6.3 Attention Deficit Hyperactivity Disorder Therapeutics - Phase I Clinical Pipeline
5.6.4 Attention Deficit Hyperactivity Disorder Therapeutics - Preclinical Pipeline
5.6.5 Attention Deficit Hyperactivity Disorder Therapeutics - Discovery Pipeline
5.7 Key Takeaway

6 Attention-Deficit Hyperactivity Disorder Market: Implications for Future Market Competition

7 Attention Deficit Hyperactivity Disorder Market: Future Players in ADHD Market

7.1 Introduction
7.2 Abbott Laboratories
7.2.1 Overview
7.2.2 CNS Portfolio
7.2.3 Attention Deficit Hyperactivity Disorder Product Portfolio
7.3 Psychogenics Inc
7.3.1 Overview
7.3.2 CNS Portfolio
7.3.3 Attention Deficit Hyperactivity Disorder Product Portfolio
7.4 Cortex Pharmaceuticals
7.4.1 Overview
7.4.2 CNS Portfolio
7.4.3 Attention Deficit Hyperactivity Disorder Product Portfolio
7.5 AstraZeneca
7.5.1 Overview
7.5.2 CNS Portfolio
7.5.3 Attention Deficit Hyperactivity Disorder Product Portfolio

8 Attention Deficit Hyperactivity Disorder Market: Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources

List of Table


Table 1: ADHD Therapeutics Market, Global, Revenue ($bn), 2001-2009 9
Table 2: ADHD Therapeutics Market, Global, Market Forecasts ($bn), 2009-2017 10
Table 3: Major marketed products comparison in ADHD Market, 2009 22
Table 4: Attention-Deficit Hyperactivity Disorder Therapeutics Most Promising Drugs Under Clinical Development 26
Table 5: Attention Deficit Hyperactivity Disorder Therapeutics Phase III Clinical Pipeline 31
Table 6: Attention Deficit Hyperactivity Disorder Therapeutics Phase II Clinical Pipeline 32
Table 7: Attention Deficit Hyperactivity Disorder Therapeutics Phase I Clinical Pipeline 33
Table 8: Attention Deficit Hyperactivity Disorder Therapeutics Preclinical Clinical Pipeline 33
Table 9: Attention Deficit Hyperactivity Disorder Therapeutics Discovery Clinical Pipeline 33
Table 12: Abbott Laboratories CNS Pipeline Products 38
Table 13: Abbott Laboratories CNS Pipeline Products 38
Table 14: Psychogenics CNS Pipeline Products 40
Table 15: Cortex Pharmaceuticals CNS Pipeline Products 41
Table 16: AstraZeneca CNS Marketed Products 42
Table 17: AstraZeneca CNS Pipeline Products 43

List of Chart


Figure 1: ADHD Therapeutics Market, Global, Revenue ($bn), 2001-2009 9
Figure 2: ADHD Therapeutics Market, Global, Market Forecasts ($bn), 2009-2017 10
Figure 3: Opportunity and Unmet Need 12
Figure 4: Strategic Competitor Assessment of the Marketed Products for ADHD 14
Figure 5: Technology Trends Analytic Framework of the ADHD Pipeline 24
Figure 6: Technology Trends Analytic Framework of the ADHD Pipeline Description 25
Figure 7: ADHD Therapeutics Market Clinical Pipeline by Mechanism of Action 30
Figure 8: ADHD Pipeline by Phase of Clinical Development 31
Figure 9: Implications for Future Market Competition in the ADHD Market 35
Figure 10: ADHD Market Clinical Pipeline by Company 37
Figure 11: GlobalData Market Forecasting Model 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *